HilleVax Inc. (HLVX)
1.75
-0.04 (-2.23%)
At close: Mar 03, 2025, 3:59 PM
1.75
0.00%
After-hours: Mar 03, 2025, 04:00 PM EST
Company Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines.
It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
The company is headquartered in Boston, Massachusetts.
HilleVax Inc.
| Country | United States |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 90 |
| CEO | Dr. Robert M. Hershberg M.D., Ph.D. |
Contact Details
Address: 75 State Street Boston, Massachusetts United States | |
| Website | https://www.hillevax.com |
Stock Details
| Ticker Symbol | HLVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001888012 |
| CUSIP Number | 43157M102 |
| ISIN Number | US43157M1027 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert M. Hershberg M.D., Ph.D. | Co-Founder, President, Chief Executive Officer & Chairman of the Board |
| Dr. Anju Chatterji Ph.D. | Chief Technology Officer |
| Shane A. Maltbie | Chief Financial Officer & Treasurer |
| Dr. Aditya Kohli Ph.D. | Co-Founder & Director |
| Paul S. Bavier J.D. | General Counsel, Secretary & Chief Administrative Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2025 | 4 | Filing |
| Feb 12, 2025 | 4 | Filing |
| Dec 05, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 8-K | Current Report |
| Aug 09, 2024 | 10-Q | Quarterly Report |
| Aug 09, 2024 | 8-K | Current Report |